ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial
The ADELE clinical trial seeks to improve outcomes for people with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy. It is hoped that this study may improve relapse rates in high-risk endometrial cancer by adding Tislelizumab immunotherapy to standard treatment.
Primary Sponsor
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
135
Expected Date of Accrual
March 2025
Trial Chairperson
Professor Linda Mileshkin, Peter MacCallum Cancer Centre, VIC, Australia
Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital
Trial Contact
qa@trog.com.au
Related Post
Trek4TROG team rise to Blue Mountains challenge
November 2024: Congratulations to the Trek4TROG team for successfully
Promising new results from RAIDER trial published
24 October 2024: Newly published findings from the TROG
